G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 mars 2024 16h20 HE
|
G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
28 févr. 2024 06h30 HE
|
G1 Therapeutics
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
27 févr. 2024 08h30 HE
|
G1 Therapeutics
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
15 févr. 2024 08h30 HE
|
G1 Therapeutics
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
12 févr. 2024 16h05 HE
|
G1 Therapeutics
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent DMC
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
08 janv. 2024 06h45 HE
|
G1 Therapeutics
G1 Therapeutics provides Corporate and Clinical Update at the 42md Annual J.P. Morgan healthcare conference.
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 09h00 HE
|
G1 Therapeutics
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 janv. 2024 16h51 HE
|
G1 Therapeutics
January 2024 Inducement Grants
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
05 déc. 2023 09h26 HE
|
G1 Therapeutics
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 déc. 2023 16h27 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...